Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation.
Dorothea HanfChristoph HeiningKarin LaaberHeiner NebelungSebastian UhrigBarbara HutterArne JahnDaniela RichterDaniela E AustFriederike HerbstStefan FröhlingHanno GlimmGunnar FolprechtPublished in: JCO precision oncology (2021)